• FITC Goat Anti-Mouse IgG: TIL Assay Strategy

  2026-08-14

  Explore how the FITC Goat Anti-Mouse IgG (H+L) Antibody supports quantitative spatial and cytometric readouts in TIL research. This guide connects secondary-antibody design with tumor-microenvironment studies, assay controls, and practical workflow decisions.

• Biotin-16-UTP for RNA Interaction Workflows

  2026-08-13

  Biotin-16-UTP enables affinity-based RNA detection, purification, and interaction analysis from a single in vitro transcription workflow. Its most useful application in lncRNA research is converting a mechanistic hypothesis, such as the LINC02870–EIF4G1 relationship, into testable RNA pull-down, localization, and validation assays.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-08-13

  Borchert et al. linked homologous recombination repair gene-expression patterns with olaparib sensitivity in malignant pleural mesothelioma, particularly in BAP1-mutated models. The study provides a biomarker-oriented framework for interpreting PARP inhibition alongside cisplatin and pemetrexed, while emphasizing that clinical validation remains necessary.

• JNK-IN-7 in Pathogen-Driven Apoptosis Assays

  2026-08-12

  JNK-IN-7 is a selective JNK inhibitor for separating c-Jun signaling from pathogen-induced apoptosis. This article translates phase-resolved Candida krusei evidence into a rigorous assay strategy while defining dose, pathway, and cross-model limitations.

• Disentangling Cancer Drug Response in Vitro

  2026-08-12

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of cancer drug response. This framework improves interpretation of in vitro assays by encouraging researchers to measure proliferative arrest, killing, and response timing separately rather than relying on a single viability endpoint.

• Anlotinib hydrochloride: Assay Workflows

  2026-08-11

  Build reproducible angiogenesis experiments around Anlotinib hydrochloride, from receptor phosphorylation to endothelial migration and tube formation. This workflow emphasizes concentration controls, orthogonal readouts, and troubleshooting so researchers can distinguish anti-angiogenic activity from nonspecific cytotoxicity in cancer research.

• WIP1, p38 MAPK, and Pyroptosis in Sepsis-AKI

  2026-08-11

  The reference study identifies WIP1/PPM1D as a restraint on p38 MAPK-driven renal tubular pyroptosis during sepsis-associated acute kidney injury. By combining single-cell sequencing, human and murine kidney analyses, HK2-cell experiments, and pharmacological inhibition with CCT007093, it connects PPM1D activity to NLRP3–caspase-1–GSDMD signaling and provides a framework for testing this pathway experimentally.

• DMG-PEG2000-NH2: An Assay-Aware Linker Guide

  2026-08-10

  DMG-PEG2000-NH2 is an NH2-PEG derivative for connecting lipid assemblies with biomolecular functionality. This guide focuses on assay design, formulation controls, and the practical limits of interpreting data from LNP and liposomal systems.

• ABT-263 (Navitoclax) Workflow for Apoptosis Research

  2026-08-09

  ABT-263 (Navitoclax) is a BH3-mimetic tool for testing Bcl-2, Bcl-xL, and Bcl-w dependence in cancer models. This workflow connects rational dose design, orthogonal apoptosis assays, mitochondrial priming, and resistance analysis to help researchers distinguish pathway engagement from nonspecific loss of viability.

• Biotin-16-UTP for RNA Interaction Workflows

  2026-08-08

  Biotin-16-UTP enables controlled RNA labeling for affinity capture, detection, purification, and localization experiments. This workflow-focused guide shows how to connect labeled RNA assays with mechanistic questions such as LINC02870–EIF4G1 regulation in hepatocellular carcinoma.

• ABT-737: Reading Mitochondrial Death Signals

  2026-08-07

  ABT-737 is a BCL-2 protein inhibitor that enables more than conventional apoptosis assays. This guide shows how to use its mitochondrial mechanism alongside recent insights into transcription-independent cell death to design better-controlled cancer experiments.

• BIIE 0246: Neuropeptide Y Y2 Receptor Antagonist in Function

  2026-08-07

  BIIE 0246 enables precise dissection of neuropeptide Y Y2 receptor signaling in feeding, anxiety, and cardiac-neural models. This guide offers protocol-ready insights, troubleshooting strategies, and leverages the latest cross-domain findings for advanced experimental design.

• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-08-06

  This study reveals that the transcription factor HOXC8 prevents pyroptotic cell death in non-small cell lung carcinoma (NSCLC) by suppressing caspase-1 expression. The findings clarify the epigenetic mechanisms linking HOXC8 to tumor survival and provide new perspectives for inflammation research and cancer biology.

• A-1210477: Decoding MCL-1 Inhibition for Precision Apoptosis

  2026-08-06

  Explore how the potent MCL-1 inhibitor A-1210477 enables advanced apoptosis induction in cancer cells. This article uniquely dissects assay optimization, mechanistic selectivity, and practical limitations, providing actionable insights for researchers in cancer cell survival regulation.

• LG 101506 (RXR Modulator): Unlocking RXR Signaling for Immun

  2026-08-05

  Explore the science of LG 101506, a high-purity RXR modulator, and its pivotal role in dissecting nuclear receptor signaling and retinoid biology. This article uniquely connects LG 101506 to recent advances in immuno-oncology, providing in-depth analysis and practical assay insights.

16337 records 1/1090 page Next 12345 下5页 Last page